The first finding in the 2025 EHS Global Census that stopped us was the gender split. Of the participants who scored in the severe range for electrohypersensitivity symptoms, 88% were women. That number is not a footnote. It is a clue to the mechanism, and it is the kind of clue that EHS skeptics have been waiting for. A condition that picks out half the population at near-nine-to-one odds is not random reporting bias. Something specific is happening to the people who report severe EHS, and the something is patterned.
SPECTRA exists because patterns like that one deserve serious investigation, and because for decades they have not received it.
The question SPECTRA is built to answer
People show up at clinics with the same cluster of complaints. Sleep that breaks apart in environments saturated with wireless signal. Headaches that track exposure rather than stress. Cognitive fog around certain devices. Tinnitus that arrives with a router and leaves with a power cut. Across thousands of these accounts, the symptom set is consistent enough that the World Health Organization gave it a name at a 2004 international workshop in Prague: idiopathic environmental intolerance attributed to electromagnetic fields, IEI-EMF in shorthand. Medicine, having named it, then largely ignored it.
The result is the diagnostic limbo that any EHS patient knows. A real symptom cluster. A real exposure variable. No accepted diagnostic code, no recognized treatment protocol, no insurance pathway. Patients oscillate between dismissal and psychological framing, sometimes within the same appointment. SPECTRA’s working assumption is that this gap is a research failure, not a patient failure.
The pillar covers the body’s response to artificial electromagnetic fields across the spectrum: long-term exposure, acute exposure, developmental exposure, and the question of who responds and why.
What the literature actually shows
Two reference points anchor the field.
In 2011, the International Agency for Research on Cancer classified radiofrequency electromagnetic fields as possibly carcinogenic to humans (Group 2B), based on limited evidence of carcinogenicity in humans and in animals. The vote at IARC was not unanimous and the classification has been contested in both directions since. What has accumulated in the intervening years are more case-control studies, more animal data, and a clearer picture of which dose ranges and tumor types matter. A 2019 paper by Miller and colleagues in Frontiers in Public Health recommended that IARC re-evaluate its 2011 classification, citing accumulated evidence from rodent carcinogenicity studies showing significantly increased rates of schwannomas and malignant gliomas, along with epidemiological signals for heavy long-term mobile phone users.
Extremely low frequency magnetic fields, the kind that surround power lines and household wiring, carry the same Group 2B classification. IARC made that call in 2002, based on pooled analyses of epidemiological studies showing an association with increased childhood leukaemia risk at average residential magnetic field strengths above 0.3 to 0.4 microtesla. The threshold is low enough that millions of children live above it without anyone measuring.
Two classifications. Two distinct exposure regimes. Both labeled “possibly carcinogenic.” This is the baseline regulatory science. Most public discussion of EMF safety treats it as either alarmist or settled, and it is neither.
EHS is the harder question, because cancer endpoints take decades to establish and symptom clusters take a methodology that medicine has been slow to develop. A 2020 review by Stein and Udasin in Environmental Research summarized the proposed mechanisms: cellular effects of EMF at ELF and RF frequencies, oxidative stress, calcium channel activation, blood-brain barrier permeability changes, and sensitization patterns analogous to those described in Multiple Chemical Sensitivity. The authors conclude that the mechanisms underlying EHS symptoms are biologically plausible. None of the proposed pathways is yet established as the EHS mechanism. Several are partially supported. The honest summary is that EHS sits where chronic fatigue syndrome sat in the 1990s: a real cluster, contested status, and a slowly assembling biology.
What the Census changed
The EHS Global Census 2025 is the foundation’s flagship project and the largest structured dataset on EHS the field has produced. Three surveys ran in parallel, gathering 537 responses across the three instruments from participants in more than 20 countries. A cross-survey cohort of 94 completed all three. The point of running three was triangulation: general exposure patterns in Survey A (n=283), symptom mapping in Survey B (n=141), clinical profile in Survey C (n=113). Where the three agree, the signal is durable.
Three findings carry the weight of the dataset. (Citations below are from EFEIA’s 2025 EHSGC Report.)
Sleep disruption explains 40.7% of the variance in symptom severity across the cohort. An effect size of that magnitude is large for a behavioral health variable in a heterogeneous population. It points at the autonomic nervous system as the system under load, consistent with the sensitization mechanisms reviewed by Stein and Udasin and with the chronic insomnia patterns reported by patients for years.
The 88% female predominance in severe cases holds across all three surveys. Sex differences of this magnitude in symptom presentation usually trace to one of three things: hormonal modulation of the response, sex-linked sensory processing differences, or differential exposure patterns. The Census data cannot yet distinguish between them. It does establish that the difference is not a sampling artifact.
Eight distinct profiles in the EMF response spectrum emerged from cluster analysis of the symptom data. The eight are not severity levels. They are qualitatively different response patterns, separated by which body systems are recruited and in what order. One profile is dominated by sleep and autonomic symptoms. Another is dominated by cognitive symptoms. A third is dominated by pain and skin response. EHS research has been missing the work of phenotyping this heterogeneity, and heterogeneous samples wash out real effects in pooled analyses.
These three findings are the spine of SPECTRA. Every other project in the pillar exists because the Census raised a question the Census cannot answer.
The five projects under SPECTRA
The pillar has seven projects on the books. Three are active. Four are planned.
EHS Global Census is the ongoing data collection that produced the 2025 results. The instruments are running for the next cohort. The dataset will deepen over the next three years.
Youth Exposure Education addresses the population that worries the field most: children and adolescents. Their nervous systems are still developing. Their skulls are thinner. Their projected exposure histories are longer than any previous generation’s. Heavy device use begins before puberty for most of them. According to Miller and colleagues (2019), a cell phone held against a child’s head exposes deeper brain structures to greater radiation doses per unit volume than for an adult, and the young, thin skull’s bone marrow absorbs a roughly 10-fold higher local dose. The project develops exposure-reduction protocols for families and schools, with materials calibrated for the ages involved.
EMF Risk Assessment is the methodology arm. Standards-grade exposure evaluation for residential and occupational environments, designed to be reproducible across practitioners and defensible in policy contexts. Without a shared method, every EHS measurement is a one-off.
Four projects are planned. Central Sensitization & EHS will test whether the symptom cluster reflects sensitization of central nervous system pathways, using the experimental tools pain research has built over the last twenty years. EHS Phenotype Research will take the eight Census profiles into clinical settings to ask whether they predict response to specific exposure-reduction strategies. The Tinnitus Management Environmental Protocol Research will build a standardized exposure-reduction protocol for people whose tinnitus forms part of an EHS profile, a symptom the population evidence has yet to settle. And, last, the Autism Spectrum Disorders and Non-Thermal Electromagnetic Pollution will ask a narrow question against a consensus that finds no established causal link: among children already diagnosed, does structured exposure management change symptom severity or daily functioning?
The seven together form a single research program with a single question at the center: what is happening to the people who report EHS, and what reduces their symptom load?
Where SPECTRA sits in the framework
EFEIA’s five pillars are not parallel departments. They are interlocking.
SPECTRA studies the body under EMF load. TERRA studies what happens to ecosystems under the same load, and reminds the human-centered work that we live inside biological systems we did not design. NEXUS studies the high-density exposure environments where SPECTRA’s findings show up in concentrated form, mainly vehicles. LUMINA develops biophoton measurement, which would give SPECTRA something the field has never had: a non-invasive cellular-level biomarker for response to exposure. QUANTIS asks whether the exposure metrics that define all four other pillars are themselves the right ones.
None of the five works on its own. The Census tells SPECTRA that 88% of severe cases are women, and it cannot say why. LUMINA, when its detection methods mature, may be able to. Until that loop closes, the pillar runs on epidemiology and self-report. After it closes, the pillar runs on measurement.
What remains open
The honest list of what SPECTRA does not yet have is long.
Diagnostic recognition. No country’s medical system codes EHS as a discrete condition. Patients are routed through psychiatry, neurology, allergy, and pain medicine without anyone owning the case.
Replication of the Census cluster analysis in an independent population. The eight profiles need to be reproduced by a different research team using different recruitment to count as established.
A clinical biomarker. Symptom reports and exposure measurements are necessary and insufficient. The field needs a measurement that does not depend on the patient’s testimony.
Differentiation from adjacent conditions. A 2025 study in Frontiers in Public Health found that people who self-report EHS are significantly overrepresented in the group of people who can be considered highly sensitive on standard sensory processing sensitivity measures. The finding raises the open question of whether EHS is a discrete condition, a presentation of broader sensory processing sensitivity, or both depending on the individual. That question has policy consequences.
Engagement with the working hypothesis that some EHS patients are responding to factors other than EMF. The pillar takes that hypothesis seriously. It also takes seriously the evidence that points the other way: the biologically plausible mechanisms summarized by Stein and Udasin, the symptom consistency across unrelated populations, and the dose-response signals in the literature reviewed by Miller and colleagues. Both possibilities can be partially true. The field needs to find out where each applies.
How to participate
The Census is open. If you experience symptoms you attribute to artificial electromagnetic exposure, the surveys are the most direct way to contribute data to the research record. The dataset is anonymized, aggregated, and used to refine the instruments for the next cohort.
For clinicians and researchers: SPECTRA welcomes collaboration on the Central Sensitization and Phenotype Research arms. Both projects are at the design stage and the protocols benefit from input.
For practitioners working with patients who present with EHS symptoms: the Licensed Professionals network includes specialists trained in EFEIA’s evaluation methods, and the directory is public.
The work of this pillar is the slow work of converting a contested symptom cluster into a recognized clinical condition with a known mechanism and a defensible treatment pathway. The Census made the cluster visible at a scale that is hard to dismiss. The next decade is about converting visibility into recognition.
SPECTRA is one of five pillars in the EFEIA Research Institute. Read about TERRA, NEXUS, LUMINA, and QUANTIS for the other four domains of the framework. Take the EHS Global Census survey. Find a licensed professional in your region.